YMMUNO BIOTECH
A Biotech start-up focused on developing new science-based products. Immunotherapies and Orally passive immunization is our cup of tea. Nowadays we are working on a new therapy to improve life quality in Crohn´s Disease patients and improving a new methodology to reduce the use of antibiotics in hospitalized elderly patients.
YMMUNO BIOTECH
Social Links:
Industry:
Biotechnology Dietary Supplements Pharmaceutical
Founded:
2019-02-05
Address:
Florianópolis, Santa Catarina, Brazil
Country:
Brazil
Website Url:
http://www.ymmuno.com
Total Employee:
1+
Status:
Active
Contact:
+5548999187299
Email Addresses:
[email protected]
Total Funding:
60 K BRL
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Amazon SSL By Default GoDaddy DNS AWS Global Accelerator OpenResty GoDaddy SSL Google Adsense
Similar Organizations
Aquit
Aquit develops preventive treatments for infections in fish that replace antibiotics, improve survival rates, and boost natural immunity.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Zhiyi Pharmaceutics
Zhiyi Pharmaceutics focuses on the research and development of second-generation probiotics and Live Biotherapeutics.
Current Employees Featured
Founder
Investors List
FAPESC - Fundação de Amparo à Pesquisa e Inovação
FAPESC - Fundação de Amparo à Pesquisa e Inovação investment in Seed Round - Ymmuno Biotech
Official Site Inspections
http://www.ymmuno.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 3.33.130.190
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Ymmuno Biotech"
HOME | Ymmunobio
At Ymmunobio, our research is based on our deep understanding of immuno-oncology and precision cancer treatments. We leverage our profound knowledge of biologics, focusing on unique and first-in-class targets while selecting the …See details»
Ymmuno Biotech - Crunchbase Company Profile & Funding
Ymmuno Biotech closed its last funding round on Aug 14, 2020 from a Seed round. Who are Ymmuno Biotech 's competitors? Alternatives and possible competitors to Ymmuno Biotech …See details»
Ymmunobio - Crunchbase Company Profile & Funding
Ymmunobio is a preclinical-stage oncology biotech startup committed to creating advanced cancer patient treatments. It makes extensive progress in …See details»
ABOUT US | Ymmunobio
Ymmunobio is committed to developing preclinical breakthroughs toward improving how cancer therapies are developed. Dr. Katrin Rupalla & Dr. Peter Schiemann co-founded Ymmunobio in 2021 as a way to advance …See details»
Ymmunobio AG - Swiss Biotech
Https://www.ymmuno.bio +41 76 378 59 30; [email protected]; Dr. Peter Schiemann, CEO & Chairman of the Board; Some insights. ... Type of organization. Private company. Year of foundation. 2021. Number of …See details»
Ymmunobio Accepted into Innosuisse Core Coaching
Mar 8, 2023 Participation in the international program guides startups in creating and developing business traction RIEHEN, SWITZERLAND, March 8, 2023 ─ Ymmunobio, a preclinical stage …See details»
Ymmunobio - LinkedIn
Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies.See details»
Ymmunobio AG - startup.ch
Ymmunobio AG: The incidence of gastric cancer is 1.1 M and only 1 in 5 respond to therapy. In addition, gastric cancer causes 770’000 deaths every year. We founded Ymmunobio in …See details»
Ymmuno Biotech - Contacts, Employees, Board Members
Using IgY as an oral immunotherapy for infectious disease, focused in research and development to reduce antibiotics resistanceSee details»
Ymmunobio at the Swiss Biotech Day
Ymmunobio was founded in 2021 focusing on GI cancers with our lead indication of gastric cancer. Our new and first in class Antibody Drug Conjugate (ADC) candidate (YB-800) has a vast potential in addressing GI cancer.See details»
INVESTORS - Ymmunobio
Ymmunobio’s team is made up of world-class leaders in immunology, oncology, cell biology, and cancer drug development, creating an innovative pipeline of novel and first-in-class antibodies.See details»
YB-200 - Drug Targets, Indications, Patents - Synapse - Patsnap
Originator Organization. Ymmunobio AG. Active Organization. Ymmunobio AG. Inactive Organization-Drug Highest Phase Preclinical. First Approval Date ... [email protected] …See details»
Launching Canada’s Immuno-Engineering and Biomanufacturing …
Mar 27, 2023 Launching Canada’s Immuno-Engineering and Biomanufacturing Hub. On March 15, leaders from across B.C.’s biotech sector gathered at UBC to celebrate the launch of …See details»
UBC-led biomedical innovation hub to accelerate development …
Mar 15, 2023 Canada’s biotech ecosystem is poised for a major boost with the federal government announcement today that B.C. will be home to Canada’s Immuno-Engineering …See details»
Home Page - Canada’s Immunoengineering and Biomanufacturing …
Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH) is bringing together a coalition of partners to accelerate the development and manufacturing of lifesaving medicines …See details»
Ymmunobio Appoints New Chief Operating Officer
Apr 11, 2023 Martin E. Zuzulo to guide drug development operations for preclinical-stage biotech companyRIEHEN, SWITZERLAND, April 11, 2023 – Ymmunobio, a preclinical stage …See details»
Immune Deficiency Foundation
Double your impact on Giving Tuesday. This Giving Tuesday double your impact and join our year-round mission to transform lives. Your donation powers breakthrough research, vital …See details»
OUR PLATFORM | Ymmunobio
Qýÿ‡QHMûáQTÔ~X ‘“V €:R þüù÷× ƒë ¦e;®çûÇ·iÿÿýùRÔ^Æê ›-ÁŒIÉÖÒ,d€t Â#²-ƒ #¹’ÌRÇoúæ¾ÿV[êNzöEȆ¾¿»ê DPD¢â«[ IB” ÁòÇåL^ìR^Ír5=éïßߪïöçë ]»6»¹ñžsî+±µ ¨£ˆcðÑNuQ!See details»
Modified neuroimmune processes and emotional behaviour in …
1 day ago The global number of infants delivered by Caesarean-section (C-section) has significantly risen in recent years, surpassing the World Health Organization’s recommended …See details»
Successful completion of the seed funding round for Ymmunobio!
Nov 10, 2023 Basel, Switzerland & Princeton, NJ, USA, November 10, 2023 ─ Ymmunobio, a global preclinical stage oncology biotech company focused on the development of innovative …See details»